Atovaquone-Proguanil: A Promising Therapy for Persistent Relapsing Babesiosis [PDF]
Case Reports in Infectious DiseasesWe report a challenging case of persistent relapsing babesiosis in an immunocompromised host that was successfully managed with atovaquone-proguanil (Malarone).
Mahum Shahid +3 more
doaj +3 more sources
Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb. [PDF]
PLoS Neglected Tropical Diseases, 2015 Plasmodium malariae is widely distributed across the tropics, causing symptomatic malaria in humans with a 72-hour fever periodicity, and may present after latency periods lasting up to many decades.
Beatrix Huei-Yi Teo +9 more
doaj +6 more sources
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis [PDF]
Malaria Journal, 2011 The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena +8 more
doaj +4 more sources
Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings [PDF]
Veterinary Sciences, 2022 Differences in drug tolerability among vertebrate groups and species can create substantial challenges for wildlife and ex situ conservation programmes.
Anja Wiegmann +8 more
doaj +2 more sources
Early treatment failure during treatment of
Malaria Journal, 2012 The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone‐proguanil (Malarone®) has shown high efficacy against Plasmodium falciparum with only mild side ...
Wurtz Nathalie +11 more
doaj +2 more sources
Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo [PDF]
Malaria Journal, 2020 Background The drug combination atovaquone–proguanil, is recommended for treatment of uncomplicated falciparum malaria in France. Despite high efficacy, atovaquone–proguanil treatment failures have been reported.
Laurencie Massamba +12 more
doaj +2 more sources
Malarone treatment failure not associated with previously described mutations in the cytochrome b gene [PDF]
Malaria Journal, 2004 Malarone® (atovaquone-proguanil) is an effective drug for the treatment and prophylaxis of multidrug-resistant falciparum malaria. However, first cases of resistance have been reported, which are associated with mutations at codon 268 of the parasite's ...
Mockenhaupt Frank P +5 more
doaj +3 more sources
A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy [PDF]
Malaria Journal, 2018 Background Malaria chemoprophylaxis options in pregnancy are limited, and atovaquone–proguanil (AP) is not recommended because of insufficient safety evidence.
Kathrine R. Tan +3 more
doaj +2 more sources
Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. [PDF]
Cochrane Database Syst Rev, 2021 The World Health Organization (WHO) in 2015 stated atovaquone-proguanil can be used in travellers, and is an option in malaria-endemic areas in combination with artesunate, as an alternative treatment where first-line artemisinin-based combination therapy (ACT) is not available or effective.
Blanshard A, Hine P.
europepmc +6 more sources
Safety of atovaquone-proguanil during pregnancy. [PDF]
J Travel Med, 2019 Malaria during pregnancy increases the risk of maternal and foetal complications. There are very limited options for prophylaxis in pregnant travellers. Atovaquone-Proguanil (AP or Malarone®) is an effective and well-tolerated antimalarial medication, but is not recommended for use in pregnancy due to limited data on safety.
Mayer RC, Tan KR, Gutman JR.
europepmc +4 more sources